Bringing treatments designed to restore the balance of the immune system to patients who hope to restore the balance in their lives.
Equillium is actively recruiting individuals to participate in clinical trials for acute graft-versus-host disease (aGVHD) and lupus nephritis.
Itolizumab is a clinical-stage, first-in-class immune-modifying monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response.
Arising from a proprietary discovery platform, the peptides utilize a novel modality to selectively inhibit multiple disease driving cytokines, while leaving other immune regulatory pathways intact.